Linking the evidence between urinary retention and antipsychotic or antidepressant drugs: A systematic review

Neurourology and Urodynamics

Volumn 35, Issue 8, 2016, Pages 866-874

  Faure Walker, Nicholas ^a   Brinchmann, Katherine ^b   Batura, Deepak ^b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

antidepressant; antipsychotic; selective serotonin reuptake inhibitors; serotonin norepinephrine reuptake inhibitors; urinary retention

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLONAZEPAM; CLOVOXAMINE; DOXEPIN; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

ANOREXIA; ANOREXIA NERVOSA; ATYPICAL DEPRESSION; BLADDER CATHETERIZATION; DELIRIUM; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; PALLIATIVE THERAPY; PREVALENCE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL VOLUME; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; STRESS INCONTINENCE; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; URINE RETENTION;

EID: 84991256363     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22851     Document Type: Review

References (50)

1. Kaplan SA, Wein AJ, Staskin DR, et al. Urinary retention and post-void residual urine in men: Separating truth from tradition. J Urol 2008; 180:47–54.
2. Choong S, Emberton M. Acute urinary retention. BJU Int 85:186–201.
3. Verhamme KM, Sturkenboom MC, Stricker BH, et al. Drug-induced urinary retention: incidence, management and prevention. Drug Safety 2008; 31:373–88.
4. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; 47:27–38.
5. Viktrup L, Pangallo BA, Detke MJ, et al. Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim Care Companion J Clin Psychiatry 2004; 6:65–73.
6. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. Br J Psychiatry 2012; 200:393–8.
7. CA Naranjo, U Busto, EM Sellers, et al. A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 1981; 30:239–45.
8. Crawford GB, Agar MM, Quinn SJ, et al. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. J Palliat Med 2013; 16:1335–41.
9. A Georgotas, L Gerbino, B Jordan, et al. A double-blind comparison of trebenzomine and thioridazine in the treatment of schizophrenia Psychopharmacology (Berl). 1981; 73:292–4.
10. S Saddichha, M. Kumar. Antipsychotic-induced urinary dysfunction: Anticholinergic effect or otherwise? BMJ Case Rep 2009; 2009. pii: bcr02.2009.1547. doi: 10.1136/bcr.02.2009.1547. Epub 2009 May 21.
11. Shiloh R, Weizman A, Dorfman-Etrog P, et al. Association between severity of schizophrenic symptoms and urinary retention. Eur Psychiatry 2001; 16:497–500.
12. S. Sahoo. Aripiprazole in a patient susceptible to urinary side effects of antipsychotics Isr J Psychiatry Relat Sci 2007; 44:74–5.
13. F. Benazzi. Urinary retention with sertraline, haloperidol, and clonazepam combination. Can J Psychiatry 1998; 43:1051–2.
14. Hwang YJ, Dixon SN, Reiss JP, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: A population-based cohort study. Ann Intern Med 2014; 161:242–8.
15. Barak Y, Mazeh D, Plopski I, et al. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia. Am J Geriatr Psychiatry. 2006; 14:629–33.
16. Taner E, Demir EY, Cosar B. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial. Adv Ther 2006; 23:974–87.
17. D Degner, R Grohmann, S Kropp, et al. Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMPS. Pharmacopsychiatry 2004; 37(Suppl1):S39–45.
18. Lodge GJ, Freeman HL. Clovoxamine and doxepin in major depressive disorder: A double-blind controlled trial. Br J Psychiatry 1986; 148:718–21.
19. Claghorn JL, Earl CQ, Walczak DD, et al. Fluvoxamine maleate in the treatment of depression: A single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996; 16:113–20.
20. J Biederman, DB Herzog, TM Rivinus, et al. Amitriptyline in the treatment of anorexia nervosa: A double-blind, placebo-controlled study. J Clin Psychopharmacol 1985; 5:10–6.
21. Ş Aslan, M Emet, Z Cakir, et al. Suicide attempts with amitriptyline in adults: A prospective, demographic, clinical study. Turk J Med Sci 2011; 41:243–9.
22. Kruithof MK, Bruins NA, van Roon EN, Coma after overdose with duloxetine. Ann Pharmacother 2011; 45:e5.
23. Lowenstein L, Mueller ER, Sharma S, et al. Urinary hesitancy and retention during treatment with sertraline. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:827–9.
24. Garakani A, Urinary retention with a high dose of escitalopram. Gen Hosp Psychiatry 2010; 32:e11–2.
25. Trombetta D, Garrett K, Harrison M, Escitalopram-associated acute urinary retention. Consult Pharm 2013; 28:661–9.
26. Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction Rev Urol 2003; 5:S3–10.
27. Mago R, Chism LM, Pinninti NR, et al. Urinary retention associated with ziprasidone: A case report. J Clin Psychiatry 2008; 69:499–500.
28. Martín-Merino E, García-Rodríguez LA, Massó-González EL, Roehrborn CG. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009; 182:1442–8.
29. Xomalis D, Bozikas VP, Garyfallos G, et al. Urinary hesitancy and retention caused by ziprasidone. Int Clin Psychopharmacol 2006; 21:71–2.
30. Kasper S, Giamal el N, Hilger E, Reboxetine: The first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother 2000; 1:771–82.
31. Gillman P, Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151:737–48.
32. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114:559–65.
33. Inghilleri M, Conte A, Frasca V, et al. Venlafaxine and bladder function. Clin Neuropharmacol 2005; 28:270–3.
34. Bozikas V, P Petrikis, Karavatos A, Urinary retention caused after fluoxetine-risperidone combination. J Psychopharmacol (Oxford) 2001; 15:142–3.
35. Semaan WE, Doyon J, Jolicoeur F, et al. Dose-dependent urinary retention following olanzapine administration. Ann Pharmacother 2006; 40:1693.
36. Sokolski KN, Brown BJ, Melden M. Urinary retention following repeated high-dose quetiapine. Ann Pharmacother 2004; 38:899–900.
37. Lai C-H. Improvements in micturition and urinary retention after switching from amisulpiride to paliperidone in a schizophrenic patient. J Neuropsychiatry Clin Neurosci 2012; 24:E11–2.
38. Hsu W-Y, Chang T-G, Chiu N-Y. Aripiprazole associated urine retention in a male schizophrenia patient. Gen Hosp Psychiatry 2013; 35:e11–2.
39. Hermesh H, Aizenberg D, Weizman A, et al. Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent. Drug Intell Clin Pharm 1987; 21:877–9.
40. Alexander J, McKenny B. Venlafaxine associated urinary symptoms. Aust N Z J Psychiatry 2010; 44:1145. doi: 10.3109/00048674.2010.518949
41. Oulis P, Leonardos A, Koulouris GC, et al. Mirtazapine-associated urinary retention. J Neuropsychiatry Clin Neurosci 2010; 22:352o.e21–352.e22. doi: 10.1176/appi.neuropsych.22.3.352-o.e21.
42. Aggarwal A, Khandelwal A, Jiloha RC. Milnacipran-associated urinary retention: A case report. J Clin Psychopharmacol 2010; 30:641.
43. Chung AKK, Chua S-E. Acute urinary retention associated with selective serotonin reuptake inhibitors and ziprasidone. J Clin Psychopharmacol 2007; 27:517–9.
44. Lenze E, Reversal of SSRI-associated urinary retention with mirtazapine augmentation. J Clin Psychopharmacol 2012; 32:434.
45. Wang S-M, Lee K-U, Jeon Y-W, et al. Severe urinary retention requiring urinary catheterization associated with combined treatment of depression with duloxetine and quetiapine. Psychiatry Clin Neurosci 2013; 67:191.
46. Benazzi F, Urinary retention with fluoxetine-haloperidol combination in a young patient. Can J Psychiatry 1996; 41:606–7.
47. Silvestri R, Raffaele M, De Domenico P, et al. Serotoninergic agents in the treatment of Gilles de la Tourette's syndrome. Acta Neurol (Napoli) 1994; 16:58–63.
48. Yalcin O. Micturition difficulty and urinary retention associated with aripiprazole and citalopram treatment in a male adolescent with asperger syndrome. J Child Adolesc Psychopharmacol 2014; 24:598–9.
49. Desarkar P, Sinha VK. Acute urinary retention associated with atomoxetine use. Aust N Z J Psychiatry 2006; 40:936.
50. Padala PR, Sadiq HJ, Padala KP. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. J Clin Psychopharmacol 2006; 26:667–8.